The stock of Oncolytics Biotech Inc.
soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selected for inclusion in a an adaptive phase 3 pancreatic cancer clinical trial. An adaptive clinical trial is one which allows modifications to the trial or statistical procedures in the trial after it has been initiated.
soared 25% Thursday, after the San Diego-based company said its pelareorep therapy has been selected for inclusion in a an adaptive phase 3 pancreatic cancer clinical trial. An adaptive clinical trial is one which allows modifications to the trial or statistical procedures in the trial after it has been initiated.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: